Harbin Gloria Pharmaceuticals (002437) — Cash Flow Reinvestment Rate
Harbin Gloria Pharmaceuticals (002437) has a Cash Flow Reinvestment Rate of 0.02x as of September 2025, reinvesting CN¥4.26 Million (capex CN¥4.26 Million ) from operating cash flow of CN¥182.89 Million. Check 002437 operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Harbin Gloria Pharmaceuticals Cash Flow Reinvestment Rate (2007–2025)
Historical reinvestment intensity for Harbin Gloria Pharmaceuticals across 19 annual periods. Explore Harbin Gloria Pharmaceuticals long-term investment intensity to see how much of total assets are deployed in long-term investments.
Annual Cash Flow Reinvestment Rate for Harbin Gloria Pharmaceuticals (2007–2025)
Year-by-year capital reinvestment analysis for Harbin Gloria Pharmaceuticals. For live market cap and broader valuation context, see Harbin Gloria Pharmaceuticals market capitalisation.
| Year | Reinvestment Rate | Total Reinvested (CNY) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 1.26x | CN¥343.47 Million | CN¥273.36 Million | CN¥23.81 Million | ▲ +589.1% |
| 2024 | 0.18x | CN¥74.93 Million | CN¥410.94 Million | CN¥62.90 Million | ▼ -59.7% |
| 2023 | 0.45x | CN¥124.00 Million | CN¥274.18 Million | CN¥29.62 Million | ▼ -53.9% |
| 2022 | 0.98x | CN¥256.90 Million | CN¥261.62 Million | CN¥33.01 Million | ▲ +306.9% |
| 2021 | 0.24x | CN¥66.17 Million | CN¥274.18 Million | CN¥34.51 Million | ▼ -94.4% |
| 2020 | 4.29x | CN¥54.70 Million | CN¥12.76 Million | CN¥43.66 Million | ▲ +1995.1% |
| 2019 | 0.20x | CN¥124.85 Million | CN¥610.37 Million | CN¥48.43 Million | ▼ -33.3% |
| 2018 | 0.31x | CN¥356.67 Million | CN¥1.16 Billion | CN¥104.34 Million | ▼ -30.0% |
| 2017 | 0.44x | CN¥285.52 Million | CN¥651.80 Million | CN¥194.63 Million | ▲ +14.4% |
| 2016 | 0.38x | CN¥398.39 Million | CN¥1.04 Billion | CN¥185.34 Million | ▼ -39.2% |
| 2015 | 0.63x | CN¥442.37 Million | CN¥702.05 Million | CN¥283.10 Million | ▲ +237.4% |
| 2014 | 0.19x | CN¥125.89 Million | CN¥674.04 Million | CN¥125.89 Million | ▼ -48.2% |
| 2013 | 0.36x | CN¥163.35 Million | CN¥453.02 Million | CN¥163.35 Million | ▼ -48.6% |
| 2012 | 0.70x | CN¥144.37 Million | CN¥205.89 Million | CN¥144.37 Million | ▼ -46.0% |
| 2011 | 1.30x | CN¥166.90 Million | CN¥128.61 Million | CN¥166.90 Million | ▼ -39.3% |
| 2010 | 2.14x | CN¥240.88 Million | CN¥112.59 Million | CN¥240.88 Million | ▲ +494.5% |
| 2009 | 0.36x | CN¥61.47 Million | CN¥170.82 Million | CN¥61.47 Million | ▼ -45.4% |
| 2008 | 0.66x | CN¥38.08 Million | CN¥57.81 Million | CN¥38.08 Million | ▲ +161.3% |
| 2007 | 0.25x | CN¥13.17 Million | CN¥52.26 Million | CN¥13.17 Million | — |